Eris Q2 FY27 slides: profit surges 39% on diabetes strength

Eris Lifesciences reported Q2 FY27 revenue up 12.6% year over year to ₹892 crore and PAT up 39.2% to ₹187 crore; EBITDA rose 7.3% to ₹309 crore, with a 34.7% margin that was 170 bps lower year over year but ahead of guidance. Gross margin improved sequentially by 134 bps to 75.7%, while management expects about 200 bps of further benefit from the Zorvia licensing deal and Bhopal facility; first-half operating cash flow was 105% of EBITDA and net debt fell ₹111 crore. Swiss Parenterals faced EU compliance-related headwinds, with revenue flat at ₹83 crore and EBITDA margin down to 25% from 33%; Eris shares closed at ₹1,100, up 0.41%.

Analysis

The earnings quality is better than the headline PAT growth suggests: EBITDA grew much more slowly, margins contracted, and a lower tax rate amplified net profit. Treat the tax-adjusted operating trajectory—not PAT—as the valuation anchor. Working-capital improvement and cash conversion are more durable positives, but verify that debtor-day gains persist rather than reflect quarter-end timing.

The margin thesis has two distinct execution tests. Zorvia replaces manufacturing revenue with a 7% royalty, so reported revenue mix and gross margin can improve without equivalent growth in underlying demand; confirm the realized margin benefit and any transition disruption. Bhopal’s contribution depends on utilization and a completed manufacturing shift, not merely commercial start-up. Swiss Parenterals is the asymmetric near-term risk: CAPA work and the planned shutdown may weigh on utilization and margins before expanded capacity contributes. No pipeline cancellations is a management statement, not proof that customer programs or timelines are unaffected.

Over the next 1–3 months, watch Q3 Swiss performance, CAPA progress and sequential consolidated/DBF margins. Over 6–18 months, Bhopal utilization, Swiss validation and capital returns determine whether the investment cycle lifts ROCE. Semaglutide is a trial-stage option, not a near-term earnings driver; trial execution, regulatory review and competitive pricing can defer or dilute value. The contrarian case is that a low share price and headline growth may understate execution and tax-quality risks, while the market may also be underweighting prospective cash generation as capex subsides. The supplied valuation ratios alone do not establish undervaluation without peer and forward-earnings checks.

Key Decisions for Investors

• Consider a staged, modest long in Eris Lifesciences only after checking the live price, valuation versus Indian branded-pharma peers, and tax-normalized earnings. Add only if operating margins stabilize and cash conversion remains strong; the thesis is falsified by renewed debtor-day deterioration or continued EBITDA-margin slippage.
• For the 1–3 month catalyst window, keep exposure conditional on Q3 evidence: track Swiss CAPA-related shutdown impact, export/CDMO revenue continuity and DBF margin progression. Reduce or avoid adding if Swiss weakness broadens beyond the planned disruption or management delays validation milestones.
• Treat the Zorvia/Bhopal margin uplift and semaglutide program as watch items, not fully priced earnings. Verify realized gross-margin gains, Bhopal utilization and regulatory trial milestones before underwriting FY28 ROCE expansion; failure to deliver the stated margin path would undermine the rerating case.